Quick Answer
Fulgent Genetics, Inc. reported Stockholders Equity of $1.11 billion for the year ending 2025.
- Fulgent Genetics, Inc. showed a decrease of -1.9% in Stockholders Equity from 2024 to 2025.
- This data is from Fulgent Genetics, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $17.25 million | Q1 2017: $55.30 million | Q2 2017: $55.73 million | Q3 2017: $55.27 million | Q1 2018: $53.03 million | Q2 2018: $52.56 million | Q3 2018: $52.58 million | Q1 2019: $49.96 million | Q2 2019: $51.14 million | Q3 2019: $54.53 million | Q4 2019: $82.78 million | Q1 2020: $81.37 million | Q2 2020: $87.04 million | Q3 2020: $186.96 million | Q1 2021: $801.57 million | Q2 2021: $912.73 million | Q3 2021: $1.04 billion | Q1 2022: $1.31 billion | Q2 2022: $1.30 billion | Q3 2022: $1.28 billion | Q1 2023: $1.26 billion | Q2 2023: $1.26 billion | Q3 2023: $1.26 billion | Q1 2024: $1.13 billion | Q2 2024: $1.13 billion | Q3 2024: $1.14 billion | Q1 2025: $1.13 billion | Q2 2025: $1.12 billion | Q3 2025: $1.13 billion.
- Over the full 13 years of available data (2013 to 2025), Fulgent Genetics, Inc.'s Stockholders Equity has grown by 56,432.2%.
- Historical annual values: Fiscal year 2025: $1.11 billion | Fiscal year 2024: $1.13 billion | Fiscal year 2023: $1.14 billion | Fiscal year 2022: $1.27 billion | Fiscal year 2021: $1.16 billion | Fiscal year 2020: $569.39 million | Fiscal year 2019: $82.78 million | Fiscal year 2018: $51.15 million | Fiscal year 2017: $54.18 million | Fiscal year 2016: $54.48 million | Fiscal year 2015: $5.15 million | Fiscal year 2014: $1.68 million | Fiscal year 2013: $1.97 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: